Cargando…
A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy
Background: Previous studies have partly explored the role of B-cell CLL/lymphoma 7 protein family member B (BCL7B) in tumorigenesis and development. However, the prognosis and immunoregulatory value of BCL7B in pan-cancer patients remains unclear. Methods: Through The Cancer Genome Atlas (TCGA) and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334570/ https://www.ncbi.nlm.nih.gov/pubmed/35910232 http://dx.doi.org/10.3389/fgene.2022.906174 |
_version_ | 1784759130807861248 |
---|---|
author | Yang, Dinglong Li, Hetong Chen, Yujing Li, Chunjiang Ren, Weiping Huang, Yongbo |
author_facet | Yang, Dinglong Li, Hetong Chen, Yujing Li, Chunjiang Ren, Weiping Huang, Yongbo |
author_sort | Yang, Dinglong |
collection | PubMed |
description | Background: Previous studies have partly explored the role of B-cell CLL/lymphoma 7 protein family member B (BCL7B) in tumorigenesis and development. However, the prognosis and immunoregulatory value of BCL7B in pan-cancer patients remains unclear. Methods: Through The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, the distinct expression of BCL7B gene in 33 tumors and adjacent normal tissues was analyzed. The Kaplan–Meier method (univariate Cox regression analysis and Kaplan–Meier curve) was used to identify the cancer types whose BCL7B gene expression was related to prognosis. The receiver operating characteristic (ROC) curve was used to elucidate the diagnosis value of BCL7B gene. Spearman’s rank correlation coefficient was used to explore the relationship between BCL7B gene expression and immune cell infiltration, immune checkpoints, DNA methylation, DNA repair genes, immune-activating genes, immune-suppressing genes, immune subtypes, tumor mutation burden (TMB), and microsatellite instability (MSI). The Wilcoxon rank sum test and Kruskal–Wallis test were used to compare the expression of BCL7B gene in tumor tissues with different clinicopathological features. Gene set enrichment analysis (GSEA) was conducted to identify the tumor-related pathways in pan-cancer. The Human Protein Atlas (HPA) database was used to verify the BCL7B gene expression at the protein level. Results: High expression of BCL7B was associated with an inferior prognosis in glioblastoma multiforme (GBM), glioma (GBMLGG), kidney chromophobe (KICH), brain lower grade glioma (LGG), oral squamous cell carcinoma (OSCC), rectum adenocarcinoma (READ), and uveal melanoma (UVM). Low expression of BCL7B was associated with a poor prognosis in kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and sarcoma (SARC). The BCL7B gene expression had varying degrees of correlation with 24 immune cell subsets in 37 tumor environments such as adrenocortical carcinoma (ACC) and bladder urothelial carcinoma (BCLA). Spearman’s rank correlation coefficient showed that BCL7B gene expression had different degrees of correlation with 47 immune checkpoints, 46 immune-activating genes, 24 immune-suppressing genes, 5 DNA repair genes, and DNA methylation, TMB, and MSI in 39 tumors. GSEA suggested that BCL7B was notably associated with cancer-related and immune-related pathways. Conclusion: In summary, BCL7B gene has a high diagnostic and prognostic value in pan-cancer and is related to the infiltration of 24 immune cell subsets in pan-cancer. |
format | Online Article Text |
id | pubmed-9334570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93345702022-07-30 A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy Yang, Dinglong Li, Hetong Chen, Yujing Li, Chunjiang Ren, Weiping Huang, Yongbo Front Genet Genetics Background: Previous studies have partly explored the role of B-cell CLL/lymphoma 7 protein family member B (BCL7B) in tumorigenesis and development. However, the prognosis and immunoregulatory value of BCL7B in pan-cancer patients remains unclear. Methods: Through The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, the distinct expression of BCL7B gene in 33 tumors and adjacent normal tissues was analyzed. The Kaplan–Meier method (univariate Cox regression analysis and Kaplan–Meier curve) was used to identify the cancer types whose BCL7B gene expression was related to prognosis. The receiver operating characteristic (ROC) curve was used to elucidate the diagnosis value of BCL7B gene. Spearman’s rank correlation coefficient was used to explore the relationship between BCL7B gene expression and immune cell infiltration, immune checkpoints, DNA methylation, DNA repair genes, immune-activating genes, immune-suppressing genes, immune subtypes, tumor mutation burden (TMB), and microsatellite instability (MSI). The Wilcoxon rank sum test and Kruskal–Wallis test were used to compare the expression of BCL7B gene in tumor tissues with different clinicopathological features. Gene set enrichment analysis (GSEA) was conducted to identify the tumor-related pathways in pan-cancer. The Human Protein Atlas (HPA) database was used to verify the BCL7B gene expression at the protein level. Results: High expression of BCL7B was associated with an inferior prognosis in glioblastoma multiforme (GBM), glioma (GBMLGG), kidney chromophobe (KICH), brain lower grade glioma (LGG), oral squamous cell carcinoma (OSCC), rectum adenocarcinoma (READ), and uveal melanoma (UVM). Low expression of BCL7B was associated with a poor prognosis in kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and sarcoma (SARC). The BCL7B gene expression had varying degrees of correlation with 24 immune cell subsets in 37 tumor environments such as adrenocortical carcinoma (ACC) and bladder urothelial carcinoma (BCLA). Spearman’s rank correlation coefficient showed that BCL7B gene expression had different degrees of correlation with 47 immune checkpoints, 46 immune-activating genes, 24 immune-suppressing genes, 5 DNA repair genes, and DNA methylation, TMB, and MSI in 39 tumors. GSEA suggested that BCL7B was notably associated with cancer-related and immune-related pathways. Conclusion: In summary, BCL7B gene has a high diagnostic and prognostic value in pan-cancer and is related to the infiltration of 24 immune cell subsets in pan-cancer. Frontiers Media S.A. 2022-07-15 /pmc/articles/PMC9334570/ /pubmed/35910232 http://dx.doi.org/10.3389/fgene.2022.906174 Text en Copyright © 2022 Yang, Li, Chen, Li, Ren and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Yang, Dinglong Li, Hetong Chen, Yujing Li, Chunjiang Ren, Weiping Huang, Yongbo A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy |
title | A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy |
title_full | A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy |
title_fullStr | A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy |
title_full_unstemmed | A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy |
title_short | A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy |
title_sort | pan-cancer analysis of the oncogenic role of bcl7b: a potential biomarker for prognosis and immunotherapy |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334570/ https://www.ncbi.nlm.nih.gov/pubmed/35910232 http://dx.doi.org/10.3389/fgene.2022.906174 |
work_keys_str_mv | AT yangdinglong apancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT lihetong apancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT chenyujing apancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT lichunjiang apancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT renweiping apancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT huangyongbo apancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT yangdinglong pancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT lihetong pancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT chenyujing pancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT lichunjiang pancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT renweiping pancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy AT huangyongbo pancanceranalysisoftheoncogenicroleofbcl7bapotentialbiomarkerforprognosisandimmunotherapy |